세포 및 유전자 치료 제3자 물류 시장 규모, 점유율, 동향 분석 보고서 : 유형별, 제품별, 온도 범위별, 치료 영역별, 최종 용도별, 지역별, 부문 예측(2025-2030년)

Cell And Gene Therapy Third-Party Logistics Market Size, Share & Trends Analysis Report By Type, By Product, By Temperature Range, By Therapeutic Area, By End-use, By Region, And Segment Forecasts, 2025 - 2030

US $ 5,950 ￦ 8,242,000

Unprintable PDF & Excel (Single User License)

보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.

US $ 6,950 ￦ 9,627,000

Printable PDF & Excel (5-User License)

보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.

US $ 8,950 ￦ 12,398,000

Printable PDF & Excel (Enterprise License)

보고서 구매 기업 및 그 자회사, 관계사가 사용할 수 있는 라이선스이며, PDF 및 엑셀 텍스트 등의 복사 및 붙여넣기, 인쇄가 가능합니다.

한글목차

세포 및 유전자 치료 제3자 물류 시장 성장과 동향

Grand View Research, Inc.의 최신 보고서에 따르면 세계의 세포 및 유전자 치료 제3자 물류 시장은 2025-2030년에 걸쳐 CAGR 11.05%를 나타내 2030년에는 200억 4,000만 달러에 달할 것으로 예측되고 있습니다.

이 시장의 성장은 주로 세포 및 유전자 치료에 대한 수요 증가로 인한 것으로, 정확한 취급, 엄격한 온도 관리, 제조업체·병원·치료 센터 간의 원활한 연계가 요구됩니다. 로지스틱스에 실패가 있으면, 고가로, 구명의 가능성이 있는 치료법을 잃게 될 수도 있습니다.

게다가 CGT의 임상 검사와 상업 인가 파이프라인이 증가하고 있기 때문에 물류 공급자는 그 능력을 확대하고 품질을 손상시키지 않고 증가하는 치료를 확실히 환자에게 전달하는 것이 요구되고 있습니다. CGT 공급망의 복잡성에 대응할 수 있는 전문적인 3PL 파트너를 요구할 수 없게 되어 물류 효율을 최적화하면서 엄격한 규제 요건에의 규정 준수를 확보하고 있습니다. 미국 FDA, EMA 및 기타 세계의 규제 기관은 효능과 안전성을 유지하기 위해 CGT의 운송 및 보관에 엄격한 지침을 부과하고 있습니다. 이는 포장에서 실시간 추적에 이르기까지 공급망 관리의 모든 측면을 관리하는 것입니다.

게다가 파트너십과 제휴, 서비스 확대, 제품 출시, 파이프라인 제품 증가 등 시장 진출기업에 의한 이니셔티브 증가가 시장 성장에 기여하고 있습니다. 인수 : 이 인수는 첨단 치료를 위한 인프라를 강화하는 것을 목표로 하고 있습니다.

세포 및 유전자 치료 제3자 물류 시장 보고서 하이라이트

• 유형별로는 세포치료와 유전자 치료의 제품 파이프라인 증가에 수반해, 시장 각사에 의한 연구 개발 활동이 활성화하고 있는 것으로부터, 임상 부문(segment)이 시장을 석권하고 있습니다.
• 제품별로는 세포요법이 2024년에 시장을 석권했지만, 이는 규제 당국에 의한 승인 증가와 상업화에 대한 대처의 확대에 의한 것입니다.
• 온도 범위별로는 초저온이나 극저온을 필요로 하지 않는 유전자 치료, 생물 제제, 재생 의료 제품 수요가 증가하고 있기 때문에 2024년에는 상온 보존이 최대 시장 점유율을 차지했습니다.
• 치료 영역별로는 암 영역이 2024년에 시장을 석권했지만, 이것은 다양한 암, 특히 혈액암이나 고형암을 치료하기 위한 선진 치료가 급속히 채용되고 있기 때문입니다.
• 최종 용도별로는 생물 제제나 특수 의약품의 온도 관리된 보관·수송에의 의존도가 높기 때문에 바이오 의약품 기업이 2024년에 최대 시장 점유율을 차지했습니다.

목차

제1장 조사 방법과 범위

제2장 주요 요약

제3장 시장 변수, 동향, 범위

• 시장 계통의 전망
  • 모 시장 전망
  • 관련/보조시장 전망
• 시장 동향과 전망
• 시장 역학
  • 시장 성장 촉진요인 분석
  • 시장 성장 억제요인 분석
• 기술
• 가격 모델 분석
• 산업 분석도구
  • Porter's Five Forces 분석
  • PESTEL 분석
  • COVID-19의 영향 분석

제4장 세포 및 유전자 치료 제3자 물류 시장 : 유형별, 추정 및 동향 분석

• 부문 대시보드
• 세포 및 유전자 치료 제3자 물류 시장 : 유형 변동 분석
• 세포 및 유전자 치료 제3자 물류의 규모와 동향 분석 보고서 - 유형별(2018-2030년)
• 임상
• 상업

제5장 세포 및 유전자 치료 제3자 물류 시장 : 제품별, 추정 및 동향 분석

• 부문 대시보드
• 세포 및 유전자 치료 제3자 물류 시장 : 제품 변동 분석
• 세포 및 유전자 치료 제3자 물류의 규모와 동향 분석 보고서 - 제품별(2018-2030년)
• 세포 치료
• 유전자 치료

제6장 세포 및 유전자 치료 제3자 물류 시장 : 온도 범위별, 추정 및 동향 분석

• 부문 대시보드
• 세포 및 유전자 치료 제3자 물류 시장 : 온도 범위 변동 분석
• 세포 및 유전자 치료 제3자 물류의 규모와 동향 분석 보고서 - 온도 범위별(2018-2030년)
• 주변 저장
• 냉장 저장
• 초저온 저장
• 극저온 저장

제7장 세포 및 유전자 치료 제3자 물류 시장 : 치료 영역별, 추정 및 동향 분석

• 부문 대시보드
• 세포 및 유전자 치료 제3자 물류 시장 : 치료 영역 변동 분석
• 세포 및 유전자 치료 제3자 물류의 규모와 동향 분석 보고서 - 치료 영역별(2018-2030년)
• 종양학
• 신경학
• 심혈관 질환
• 안과
• 전염병
• 기타

제8장 세포 및 유전자 치료 제3자 물류 시장 : 최종 용도별, 추정 및 동향 분석

• 부문 대시보드
• 세포 및 유전자 치료 제3자 물류 시장 : 최종 용도 변동 분석
• 세포 및 유전자 치료 제3자 물류의 규모와 동향 분석 보고서 - 최종 용도별(2018-2030년)
• 바이오제약 회사
• CDMO/CMO
• 기타

제9장 지역 비즈니스 분석

• 지역 대시보드
• 시장 규모와 예측과 동향 분석(2018-2030년)
• 북미
  • 북미의 세포 및 유전자 치료 제3자 물류 시장 추정·예측(2018-2030년)
  • 미국
  • 캐나다
  • 멕시코
• 유럽
  • 유럽의 세포 및 유전자 치료 제3자 물류 시장 추정·예측(2018-2030년)
  • 독일
  • 영국
  • 프랑스
  • 이탈리아
  • 스페인
  • 덴마크
  • 스웨덴
  • 노르웨이
• 아시아태평양
  • 아시아태평양의 세포 및 유전자 치료 제3자 물류 시장 추정·예측(2018-2030년)
  • 일본
  • 중국
  • 인도
  • 한국
  • 호주
  • 태국
• 라틴아메리카
  • 라틴아메리카의 세포 및 유전자 치료 제3자 물류 시장 추정·예측(2018-2030년)
  • 브라질
  • 아르헨티나
• 중동 및 아프리카
  • 중동 및 아프리카의 세포 및 유전자 치료 제3자 물류 시장 추정·예측(2018-2030년)
  • 남아프리카
  • 사우디아라비아
  • 아랍에미리트(UAE)
  • 쿠웨이트

제10장 경쟁 구도

• 기업 분류
• 기업의 시장 점유율/평가 분석(2024년)
• 기업 프로파일
  • Cencora Corporation
  • Cardinal Health
  • McKesson Corporation
  • EVERSANA
  • Knipper Health
  • Arvato SE
  • DHL
  • FedEx
  • Kuehne Nagel
  • United Parcel Service of America, Inc.

KTH

영문 목차

영문목차

Cell & Gene Therapy Third-Party Logistics Market Growth & Trends:

The global cell and gene therapy third-party logistics market is expected to reach USD 20.04 billion by 2030, expanding at a CAGR of 11.05% from 2025 to 2030, according to a new report by Grand View Research, Inc. The growth of the market is mainly due to rising demand for cell and gene therapies, which require precise handling, strict temperature controls, and seamless coordination between manufacturers, hospitals, and treatment centers. CGTs are patient-specific, which signifies that a single patient's cells must be collected, transported, modified, and reinfused within tight timelines. Any failure in logistics can result in the loss of an expensive, potentially life-saving therapy. The personalized nature of CGTs has increased the need for advanced cold chain logistics, with cryogenic storage and ultra-low temperature transportation becoming standard requirements.

In addition, the growing pipeline of CGT clinical trials and commercial approvals encourages logistics providers to scale their capabilities, ensuring that the increasing volume of therapies reaches patients without compromising quality. This shift is compelling biopharmaceutical companies to seek specialized 3PL partners that can handle the complexities of CGT supply chains, ensuring compliance with strict regulatory requirements while optimizing distribution efficiency. Moreover, the growing regulatory support is also one of the factors contributing to market growth. The U.S. FDA, EMA, and other global regulatory bodies impose stringent guidelines on the transportation and storage of CGTs to maintain their potency and safety. Regulatory compliance requires logistics providers to implement Good Distribution Practices (GDP) and Good Manufacturing Practices (GMP) standards, which govern every aspect of supply chain management, from packaging to real-time tracking. Failure to comply can result in rejected shipments, financial losses, and treatment delays for patients.

Furthermore, growing initiatives by the market players, such as partnerships and collaborations, service expansion, product launches, and increasing pipeline products, contribute to market growth. For instance, in March 2025, DHL acquired CryoPDP, a specialist in temperature-controlled logistics for life sciences. The acquisition aims to strengthen the infrastructure for handling advanced therapies. CryoPDP's expertise in ultra-cold storage and real-time monitoring solutions aligns with DHL's strategy, providing end-to-end solutions for biopharma companies.

Cell And Gene Therapy Third-Party Logistics Market Report Highlights:

• Based on type, the clinical segment dominated the market due to the increasing number of research and development activities by the market players coupled with the growing number of cell and gene therapies product pipelines.
• Based on the product, cell therapies dominated the market in 2024 due to increasing regulatory approvals and expanding commercialization efforts. The success of CAR-T cell therapies for cancer treatment played a crucial role in this growth, with companies like Novartis, Gilead Sciences, and Bristol Myers Squibb driving widespread adoption.
• Based on temperature range, ambient storage held the largest market share in 2024due to the increasing demand for gene therapies, biologics, and regenerative medicine products that do not require ultra-low or cryogenic temperatures.
• Based on the therapeutic area, the oncology segment dominated the market in 2024due to the rapid adoption of advanced therapies for treating various cancers, particularly hematologic and solid tumors.
• Based on end use, biopharmaceutical companies held the largest market share in 2024due to their high reliance on temperature-controlled storage and transportation for biologics and specialty drugs.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
  • 1.1.1. Regional Scope
  • 1.1.2. Estimates and Forecast Timeline
• 1.2. Market Definitions
• 1.3. Research Methodology
  • 1.3.1. Information Procurement
  • 1.3.2. Purchased Database
  • 1.3.3. GVR's Internal Database
  • 1.3.4. Secondary Sources
  • 1.3.5. Primary Research
• 1.4. Information or Data Analysis
  • 1.4.1. Information Analysis
  • 1.4.2. Market Formulation & Data Visualization
  • 1.4.3. Data Validation & Publishing
• 1.5. Model Details
  • 1.5.1. Commodity Flow Analysis (Model 1)
  • 1.5.2. Top Down Market Estimation (Model 2)
  • 1.5.3. Value-Chain-Based Sizing & Forecasting (Model 3)
  • 1.5.4. Multivariate Analysis (Model 4)
• 1.6. List of Secondary Sources
• 1.7. List of Abbreviations
• 1.8. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/Ancillary Market Outlook
• 3.2. Market Trends and Outlook
• 3.3. Market Dynamics
  • 3.3.1. Market Driver Analysis
  • 3.3.2. Market Restraint Analysis
• 3.4. Technology Landscape
• 3.5. Pricing Model Analysis
• 3.6. Industry Analysis Tools
  • 3.6.1. Porter's Five Forces Analysis
  • 3.6.2. PESTEL Analysis
  • 3.6.3. COVID-19 Impact Analysis

Chapter 4. Cell & Gene Therapy Third-Party Logistics Market: Type Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. Cell & Gene Therapy Third-Party Logistics Market; Type Movement Analysis
• 4.3. Cell & Gene Therapy Third-Party Logistics Size & Trend Analysis, by Type, 2018 to 2030 (USD Million)
• 4.4. Clinical
  • 4.4.1. Clinical market estimates and forecasts, 2018 to 2030 (USD Million)
• 4.5. Commercial
  • 4.5.1. Commercial market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 5. Cell & Gene Therapy Third-Party Logistics Market: Product Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. Cell & Gene Therapy Third-Party Logistics Market; Product Movement Analysis
• 5.3. Cell & Gene Therapy Third-Party Logistics Size & Trend Analysis, by Product, 2018 to 2030 (USD Million)
• 5.4. Cell Therapies
  • 5.4.1. Cell therapies market estimates and forecasts, 2018 to 2030 (USD Million)
• 5.5. Gene Therapies
  • 5.5.1. Gene therapies market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 6. Cell & Gene Therapy Third-Party Logistics Market: Temperature Range Estimates & Trend Analysis

• 6.1. Segment Dashboard
• 6.2. Cell & Gene Therapy Third-Party Logistics Market; Temperature Range Movement Analysis
• 6.3. Cell & Gene Therapy Third-Party Logistics Size & Trend Analysis, by Temperature Range, 2018 to 2030 (USD Million)
• 6.4. Ambient Storage
  • 6.4.1. Ambient storage market estimates and forecasts, 2018 to 2030 (USD Million)
• 6.5. Refrigerated Storage
  • 6.5.1. Refrigerated storage market estimates and forecasts, 2018 to 2030 (USD Million)
• 6.6. Ultra-Low Temperature Storage
  • 6.6.1. Ultra-Low temperature storage market estimates and forecasts, 2018 to 2030 (USD Million)
• 6.7. Cryogenic Storage
  • 6.7.1. Cryogenic storage market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 7. Cell & Gene Therapy Third-Party Logistics Market: Therapeutic Area Estimates & Trend Analysis

• 7.1. Segment Dashboard
• 7.2. Cell & Gene Therapy Third-Party Logistics Market; Therapeutic Area Movement Analysis
• 7.3. Cell & Gene Therapy Third-Party Logistics Size & Trend Analysis, by Therapeutic Area, 2018 to 2030 (USD Million)
• 7.4. Oncology
  • 7.4.1. Oncology market estimates and forecasts, 2018 to 2030 (USD Million)
• 7.5. Neurology
  • 7.5.1. Neurology market estimates and forecasts, 2018 to 2030 (USD Million)
• 7.6. Cardiovascular Diseases
  • 7.6.1. Cardiovascular diseases market estimates and forecasts, 2018 to 2030 (USD Million)
• 7.7. Ophthalmology
  • 7.7.1. Ophthalmology market estimates and forecasts, 2018 to 2030 (USD Million)
• 7.8. Infectious Diseases
  • 7.8.1. Infectious diseases market estimates and forecasts, 2018 to 2030 (USD Million)
• 7.9. Others
  • 7.9.1. Others market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 8. Cell & Gene Therapy Third-Party Logistics Market: End Use Estimates & Trend Analysis

• 8.1. Segment Dashboard
• 8.2. Cell & Gene Therapy Third-Party Logistics Market; End Use Movement Analysis
• 8.3. Cell & Gene Therapy Third-Party Logistics Size & Trend Analysis, by End Use, 2018 to 2030 (USD Million)
• 8.4. Biopharmaceutical Companies
  • 8.4.1. Biopharmaceutical Companies market estimates and forecasts, 2018 to 2030 (USD Million)
• 8.5. CDMOs/CMOs
  • 8.5.1. CDMOs/CMOs market estimates and forecasts, 2018 to 2030 (USD Million)
• 8.6. Others
  • 8.6.1. Others market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 9. Regional Business Analysis

• 9.1. Regional Dashboard
• 9.2. Market Size & Forecasts and Trend Analysis, 2018 to 2030
• 9.3. North America
  • 9.3.1. North America cell & gene therapy third-party logistics market estimates and forecasts, 2018 to 2030 (USD Million)
  • 9.3.2. U.S.
    • 9.3.2.1. Key country dynamics
    • 9.3.2.2. Competitive scenario
    • 9.3.2.3. Regulatory framework
    • 9.3.2.4. U.S. cell & gene therapy third-party logistics market estimates and forecasts, 2018 to 2030 (USD Million)
  • 9.3.3. Canada
    • 9.3.3.1. Key country dynamics
    • 9.3.3.2. Competitive scenario
    • 9.3.3.3. Regulatory framework
    • 9.3.3.4. Canada cell & gene therapy third-party logistics market estimates and forecasts, 2018 to 2030 (USD Million)
  • 9.3.4. Mexico
    • 9.3.4.1. Key country dynamics
    • 9.3.4.2. Competitive scenario
    • 9.3.4.3. Regulatory framework
    • 9.3.4.4. Mexico cell & gene therapy third-party logistics market estimates and forecasts, 2018 to 2030 (USD Million)
• 9.4. Europe
  • 9.4.1. Europe cell & gene therapy third-party logistics market estimates and forecasts, 2018 to 2030 (USD Million)
  • 9.4.2. Germany
    • 9.4.2.1. Key country dynamics
    • 9.4.2.2. Competitive scenario
    • 9.4.2.3. Regulatory framework
    • 9.4.2.4. Germany cell & gene therapy third-party logistics market estimates and forecasts, 2018 to 2030 (USD Million)
  • 9.4.3. UK
    • 9.4.3.1. Key country dynamics
    • 9.4.3.2. Competitive scenario
    • 9.4.3.3. Regulatory framework
    • 9.4.3.4. UK cell & gene therapy third-party logistics market estimates and forecasts, 2018 to 2030 (USD Million)
  • 9.4.4. France
    • 9.4.4.1. Key country dynamics
    • 9.4.4.2. Competitive scenario
    • 9.4.4.3. Regulatory framework
    • 9.4.4.4. France cell & gene therapy third-party logistics market estimates and forecasts, 2018 to 2030 (USD Million)
  • 9.4.5. Italy
    • 9.4.5.1. Key country dynamics
    • 9.4.5.2. Competitive scenario
    • 9.4.5.3. Regulatory framework
    • 9.4.5.4. Italy cell & gene therapy third-party logistics market estimates and forecasts, 2018 to 2030 (USD Million)
  • 9.4.6. Spain
    • 9.4.6.1. Key country dynamics
    • 9.4.6.2. Competitive scenario
    • 9.4.6.3. Regulatory framework
    • 9.4.6.4. Spain cell & gene therapy third-party logistics market estimates and forecasts, 2018 to 2030 (USD Million)
  • 9.4.7. Denmark
    • 9.4.7.1. Key country dynamics
    • 9.4.7.2. Competitive scenario
    • 9.4.7.3. Regulatory framework
    • 9.4.7.4. Denmark cell & gene therapy third-party logistics market estimates and forecasts, 2018 to 2030 (USD Million)
  • 9.4.8. Sweden
    • 9.4.8.1. Key country dynamics
    • 9.4.8.2. Competitive scenario
    • 9.4.8.3. Regulatory framework
    • 9.4.8.4. Sweden cell & gene therapy third-party logistics market estimates and forecasts, 2018 to 2030 (USD Million)
  • 9.4.9. Norway
    • 9.4.9.1. Key country dynamics
    • 9.4.9.2. Competitive scenario
    • 9.4.9.3. Regulatory framework
    • 9.4.9.4. Norway cell & gene therapy third-party logistics market estimates and forecasts, 2018 to 2030 (USD Million)
• 9.5. Asia Pacific
  • 9.5.1. Asia Pacific cell & gene therapy third-party logistics market estimates and forecasts, 2018 to 2030 (USD Million)
  • 9.5.2. Japan
    • 9.5.2.1. Key country dynamics
    • 9.5.2.2. Competitive scenario
    • 9.5.2.3. Regulatory framework
    • 9.5.2.4. Japan cell & gene therapy third-party logistics market estimates and forecasts, 2018 to 2030 (USD Million)
  • 9.5.3. China
    • 9.5.3.1. Key country dynamics
    • 9.5.3.2. Competitive scenario
    • 9.5.3.3. Regulatory framework
    • 9.5.3.4. China cell & gene therapy third-party logistics market estimates and forecasts, 2018 to 2030 (USD Million)
  • 9.5.4. India
    • 9.5.4.1. Key country dynamics
    • 9.5.4.2. Competitive scenario
    • 9.5.4.3. Regulatory framework
    • 9.5.4.4. India cell & gene therapy third-party logistics market estimates and forecasts, 2018 to 2030 (USD Million)
  • 9.5.5. South Korea
    • 9.5.5.1. Key country dynamics
    • 9.5.5.2. Competitive scenario
    • 9.5.5.3. Regulatory framework
    • 9.5.5.4. South Korea cell & gene therapy third-party logistics market estimates and forecasts, 2018 to 2030 (USD Million)
  • 9.5.6. Australia
    • 9.5.6.1. Key country dynamics
    • 9.5.6.2. Competitive scenario
    • 9.5.6.3. Regulatory framework
    • 9.5.6.4. Australia cell & gene therapy third-party logistics market estimates and forecasts, 2018 to 2030 (USD Million)
  • 9.5.7. Thailand
    • 9.5.7.1. Key country dynamics
    • 9.5.7.2. Competitive scenario
    • 9.5.7.3. Regulatory framework
    • 9.5.7.4. Thailand cell & gene therapy third-party logistics market estimates and forecasts, 2018 to 2030 (USD Million)
• 9.6. Latin America
  • 9.6.1. Latin America cell & gene therapy third-party logistics market estimates and forecasts, 2018 to 2030 (USD Million)
  • 9.6.2. Brazil
    • 9.6.2.1. Key country dynamics
    • 9.6.2.2. Competitive scenario
    • 9.6.2.3. Regulatory framework
    • 9.6.2.4. Brazil cell & gene therapy third-party logistics market estimates and forecasts, 2018 to 2030 (USD Million)
  • 9.6.3. Argentina
    • 9.6.3.1. Key country dynamics
    • 9.6.3.2. Competitive scenario
    • 9.6.3.3. Regulatory framework
    • 9.6.3.4. Argentina cell & gene therapy third-party logistics market estimates and forecasts, 2018 to 2030 (USD Million)
• 9.7. MEA
  • 9.7.1. MEA cell & gene therapy third-party logistics market estimates and forecasts, 2018 to 2030 (USD Million)
  • 9.7.2. South Africa
    • 9.7.2.1. Key country dynamics
    • 9.7.2.2. Competitive scenario
    • 9.7.2.3. Regulatory framework
    • 9.7.2.4. South Africa cell & gene therapy third-party logistics market estimates and forecasts, 2018 to 2030 (USD Million)
  • 9.7.3. Saudi Arabia
    • 9.7.3.1. Key country dynamics
    • 9.7.3.2. Competitive scenario
    • 9.7.3.3. Regulatory framework
    • 9.7.3.4. Saudi Arabia cell & gene therapy third-party logistics market estimates and forecasts, 2018 to 2030 (USD Million)
  • 9.7.4. UAE
    • 9.7.4.1. Key country dynamics
    • 9.7.4.2. Competitive scenario
    • 9.7.4.3. Regulatory framework
    • 9.7.4.4. UAE cell & gene therapy third-party logistics market estimates and forecasts, 2018 to 2030 (USD Million)
  • 9.7.5. Kuwait
    • 9.7.5.1. Key country dynamics
    • 9.7.5.2. Competitive scenario
    • 9.7.5.3. Regulatory framework
    • 9.7.5.4. Kuwait cell & gene therapy third-party logistics market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 10. Competitive Landscape

• 10.1. Company Categorization
• 10.2. Company Market Share/Assessment Analysis, 2024
• 10.3. Company Profiles
  • 10.3.1. Cencora Corporation
    • 10.3.1.1. Company overview
    • 10.3.1.2. Financial performance
    • 10.3.1.3. Service benchmarking
    • 10.3.1.4. Strategic initiatives
  • 10.3.2. Cardinal Health
    • 10.3.2.1. Company overview
    • 10.3.2.2. Financial performance
    • 10.3.2.3. Service benchmarking
    • 10.3.2.4. Strategic initiatives
  • 10.3.3. McKesson Corporation
    • 10.3.3.1. Company overview
    • 10.3.3.2. Financial performance
    • 10.3.3.3. Service benchmarking
    • 10.3.3.4. Strategic initiatives
  • 10.3.4. EVERSANA
    • 10.3.4.1. Company overview
    • 10.3.4.2. Financial performance
    • 10.3.4.3. Service benchmarking
    • 10.3.4.4. Strategic initiatives
  • 10.3.5. Knipper Health
    • 10.3.5.1. Company overview
    • 10.3.5.2. Financial performance
    • 10.3.5.3. Service benchmarking
    • 10.3.5.4. Strategic initiatives
  • 10.3.6. Arvato SE
    • 10.3.6.1. Company overview
    • 10.3.6.2. Financial performance
    • 10.3.6.3. Service benchmarking
    • 10.3.6.4. Strategic initiatives
  • 10.3.7. DHL
    • 10.3.7.1. Company overview
    • 10.3.7.2. Financial performance
    • 10.3.7.3. Service benchmarking
    • 10.3.7.4. Strategic initiatives
  • 10.3.8. FedEx
    • 10.3.8.1. Company overview
    • 10.3.8.2. Financial performance
    • 10.3.8.3. Service benchmarking
    • 10.3.8.4. Strategic initiatives
  • 10.3.9. Kuehne+Nagel
    • 10.3.9.1. Company overview
    • 10.3.9.2. Financial performance
    • 10.3.9.3. Service benchmarking
    • 10.3.9.4. Strategic initiatives
  • 10.3.10. United Parcel Service of America, Inc.
    • 10.3.10.1. Company overview
    • 10.3.10.2. Financial performance
    • 10.3.10.3. Service benchmarking
    • 10.3.10.4. Strategic initiatives

관련자료